Next, we detected METTL3 expression in 13 pairs of pre- and post-chemotherapy HR+HER2− BC tumour tissues and observed that METTL3 expression was deficient in the post-chemotherapy tissues compared to the pre-treatment tissues (Fig. 1B, C Additional file 1C). The gene discussed is METTL3; the disease is breast cancer.